[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584698":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":34,"responsibleParty":74,"collaborators":20,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":78,"sex":84,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":20,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":101,"whyStopped":20,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"Yan'an Affiliated Hospital of Kunming Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Carstor® 70-240mm, AnkuraTMⅡ60-200mm, WeFlow-TbranchTM and Fabulous® Device Surgical Implant","EXPERIMENTAL","Subjects with acute type B aortic dissection were treated with an endovascular procedure using the Carstor® 70-240mm, AnkuraTMⅡ60-200mm, WeFlow-TbranchTM 160-240mm Thoracic Aortic Endoprosthesis and the Fabulous® 45-150mm long big bare stent via femoral artery access. (Permanent implant)",[13],"Device: Hybrid TEVAR combined with long bare-metal stent intervention",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","Hybrid TEVAR combined with long bare-metal stent intervention","\\- Primary TEVAR: Primary TEVAR: Employ Carstor® 70-240mm, AnkuraTMⅡ60-200mm, WeFlow-TbranchTM 160-240mm endograft deployed with ≥2cm proximal landing zone coverage.\n\nConcurrent bare-stenting: Post-TEVAR femoral access deployment of Fabulous® (45-150mm) long bare-metal stent with:\n\nProximal overlap ≥3cm with TEVAR graft. Distal extension 2-6cm below renal artery plane. Maximum distal limit: above iliac bifurcation.\n\n\\- Intraprocedural angiography with spinal reference mapping guides precise stent positioning relative to visceral arteries and infrarenal aorta.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Xunqiang Prof. Liu, M.D.","PRINCIPAL_INVESTIGATOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","+8613888390126","liuxunqiang1001@163.com",{"name":31,"role":27,"phone":32,"phoneExt":20,"email":33},"Zheng Dr. Jia, Ph.D.","+8613669776843","jiazhenghappy@163.com",[35],{"facility":5,"status":20,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Kunming","Yunnan","650051","China","CN",{"type":42,"coordinates":43},"Point",[44,45],102.71833,25.03889,{"lat":45,"lon":44},[48,49,50,52,54,56,58,60,62,64,66,68,70,72],{"name":31,"role":27,"phone":32,"phoneExt":20,"email":33},{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"name":31,"role":51,"phone":20,"phoneExt":20,"email":20},"SUB_INVESTIGATOR",{"name":53,"role":51,"phone":20,"phoneExt":20,"email":20},"Ruhong Prof. Li, M.D.",{"name":55,"role":51,"phone":20,"phoneExt":20,"email":20},"Enshuai Dr. Zhu, M.S.",{"name":57,"role":51,"phone":20,"phoneExt":20,"email":20},"Huanjun Prof. Chen, M.S.",{"name":59,"role":51,"phone":20,"phoneExt":20,"email":20},"Ying Dr. Yanf",{"name":61,"role":51,"phone":20,"phoneExt":20,"email":20},"Min Dr. Ji, M.S.",{"name":63,"role":51,"phone":20,"phoneExt":20,"email":20},"Chunxin Dr. Yang, M.S.",{"name":65,"role":51,"phone":20,"phoneExt":20,"email":20},"Jinhui Dr. Zhang, M.D.",{"name":67,"role":51,"phone":20,"phoneExt":20,"email":20},"Lei Dr. Cong, M.S.",{"name":69,"role":51,"phone":20,"phoneExt":20,"email":20},"Jiaqi Dr. Li, M.S.",{"name":71,"role":51,"phone":20,"phoneExt":20,"email":20},"Yan Dr. Wei, M.S.",{"name":73,"role":51,"phone":20,"phoneExt":20,"email":20},"Liqiong Dr. Zhang",{"type":75,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100584698","safety-and-efficacy-of-tevar-combined-with-long-bare-metal-stents-in-the-intervention-of-atbad-100584698",false,"NCT06892730","Safety and Efficacy of TEVAR Combined With Long Bare-metal Stents in the Intervention of ATBAD","Safety and Efficacy of TEVAR Combined With Long Bare-metal Stents in the Intervention of ATBAD: a Prospective and Cohort Study","SAFE-COVER","Inclusion Criteria:\n\n* ≧18 years old, ≦80 years old;\n* Acute phase with a course of disease ≦14 days;\n* CTA confirmed diagnosis of active dissection type B in accordance with the Stanford classification in the ESC guidelines, and requiring TEVAR surgery;\n* For patients with acute non-type A and non-type B aortic dissection involving the left subclavian artery: current technologies (such as fenestration, single branch, chimney, etc.) can be used to solve the reconstruction of the left subclavian artery;\n* The distal end of the dissection exceeds the renal artery plane;\n* Signed informed consent (emergency waiver applicable), with primary intervention using CTAG devices. Adjunctive procedures may include LSA revascularization, percutaneous fenestration, aortic\u002Fperipheral stenting, surgical fenestration, or bypass grafting.\n* Medical record completeness \\>90% with mandatory CTA data;\n* Protocol compliance including follow-up adherence\n\nExclusion Criteria:\n\n* Dissection termination above renal arteries;\n* Major aortic surgery within 30 days prior (except LSA revascularization);\n* Iliofemoral stenosis\u002Fangulation precluding endovascular access;\n* Non-diagnostic CTA image quality;\n* Indeterminate symptom onset time;\n* Traumatic TBAD, intramural hematoma, or penetrating aortic ulcer;\n* Complete thoracic aortic thrombosis pre-TEVAR;\n* Re-intervention within 12 months post-TEVAR for non-aortic indications;\n* Renal failure: Baseline serum creatinine \\>2.5 mg\u002FdL (high-risk for contrast nephropathy);\n* Known device material hypersensitivity;\n* Systemic infection increasing endograft infection risk;\n* Evidence of aortic infection;\n* Connective tissue disorders (e.g., Marfan syndrome);\n* Bowel necrosis from visceral ischemia;\n* Participation in other device\u002Fdrug trials within 1 year;\n* Moribund status: ASA class 5 with \\\u003C24h life expectancy;\n* Refractory shock (SBP \\\u003C90 mmHg);\n* Pregnancy or lactation;\n* Active substance abuse.","ALL","18 Years","80 Years",{"count":88,"type":89},200,"ESTIMATED","INTERVENTIONAL",[92],"NA","The primary objective of this study is to evaluate the safety and efficacy of the TEVAR combined with extended bare-metal stenting (distal landing zone ≥2 cm below renal arteries) in patients with acute complicated type B aortic dissection (ATBAD).\n\nAdditionally, to prevent postoperative true lumen hypoperfusion in residual thoracoabdominal aortic dissection (visceral zone, infrarenal aorta, and iliac arteries) and persistent ischemic manifestations in visceral and lower extremity arteries post-endovascular repair, extended bare-metal stents are deployed to maintain adequate distal true lumen patency. This strategy ensures perfusion to visceral branches and lower limbs while preparing for future complete endovascular aortic repair.",[95],"Aortic Dissection Type B",[97,98,99,100],"ATBAD","TEVAR","Extension","Long bare metal scaffolding devices","NOT_YET_RECRUITING","2025-03-21",{"date":104,"type":105},"2025-03-25","ACTUAL",{"date":107,"type":89},"2025-03-31",{"date":109,"type":89},"2027-03-31",{"name":5,"class":6},1]